Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
Korro Bio, Inc.: Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 -U.S. Food and ...